← Evidence map

ArticleNature cancer2024

Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.

Caicun Zhou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. | OpenQuestion